Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ghrelin in Anterior Circulation Ischemic Stroke Treated With EVT
2024-515705-26-00Phase 2Authorised
- Sponsor
- Rijnstate
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of human ghrelin in ischemic stroke (2 arms), sponsored by Rijnstate. Primary endpoint: Neurological deficit at 7 days. Planned start Oct 2024; status: authorised.
02
Drugs
human ghrelin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-515705-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515705-26-00.